TriangleGemcitabine (NCT07671534)
Gemcitabine trial for Solid Tumor Cancer (NCT07671534). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults with previously treated, locally advanced or metastatic solid tumors and measurable disease.
The idea: low-dose gemcitabine and mitomycin interfere with DNA production; thalidomide inhibits signals that promote new blood vessels. Patients receive intravenous gemcitabine and mitomycin plus oral thalidomide. Scans track progression, and treatment may continue for up to one year unless disease worsens or toxicity prevents it. Researchers assess progression-free survival and safety.
This phase 2 study plans 60 patients. Neal Chawla leads at Sarcoma Oncology Research Center, Santa Monica, the sole recruiting US site.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.